Pioneering
CD30 Targeting
in Cell Therapy

Late stage clinical program with RMAT and PRIME Designation

Differentiated
Allogeneic Platform

Based on Virus specific T cells and CD30 CAR

Experienced
Leadership Team

State-of-the-art
GMP Manufacturing Facility

Press Releases & Events